, for the treatment of attention deficit hyperactivity disorder (ADHD) in adults
ENPNewswire-June 19, 2019--Shionogi Got Approval of Additional Indication of INTUNIV
in Japan for Treatment of Adult ADHD
M2 EQUITYBITES-August 13, 2018-Shire and Shionogi submit New Drug Application for INTUNIV
M2 PHARMA-August 13, 2018-Shire and Shionogi submit New Drug Application for INTUNIV
HEADCOUNT: 23,906 YEAR ESTABLISHED: 1986 REVENUES: $11,397 (+78%) NET INCOME: $327 (-75%) R&D: $1,440 (-8%) DRUGS APPROVED DRUG INDICATION Cuvitru primary immunodeficiency Xiidra dry eye disease Glassia emphysema due to severe AAT deficiency Intuniv
ADHD Ady novate hemophilia A children and surgical settings ONIVYDE with 5-FU metastatic adenocarcinoma of the pancreas and leucovorin DRUGS PENDING DRUG INDICATION Natpar hypoparathroidism SHP465 ADHD DRUGS IN PHASE IIB AND BEYOND DRUG INDICATION Glassia acute graft vs.
They included the following as empirically supported treatments (ESTs) for ADHD: Stimulant medications (e.g., by trade names, Aderall XR, Concerta, Vyvanse, Focalin and Focalin XR, and Daytrana); non-stimulant medications (e.g., by trade names Strattera, and alpha agonists Kapvay and Intuniv
); behavior therapy (e.g., behavioral parent training, and classroom contingency management); and combined treatments (of behavior therapy and stimulant medication, e.
In particular, Shire Pharmaceuticals climbed 1.05% to 4795p after securing European approval for its Intuniv
drug, a "non-stimulant drug for attention deficit hyperactivity disorder".
Non-stimulant medications include atomoxetine (Strattera) and Guanfacine (Intuniv
Guanfacine and extended-release guanfacine (Intuniv
) are also central alpha-2-adrenergic agonists commonly used as alternative or add-on treatments for ADHD.
Non-stimulant drugs--atomoxetine (Strattera) and guanfacine (Intuniv
)--are also prescribed.
And some kids do well on Intuniv
, the long-acting guanfacine formulation, but "parents don't like paying that extra price" for the newer medication, Dr.